4
|
For instance, by around June 27, 2016, the Board had reduced its capacity to four seats, maintaining only
Drexler, Bush, Doran, and Jenkins as directors. Compl. ¶ 27(a). By around September 15, 2016, John Price had departed as the Companys CFO, with no explanation by the Company for his departure. Compl. ¶ 27(b). By around
December 1, 2016, Peter Lynch had become the Companys new CFO, PAO, and PFO; however, around two weeks later, Stacey Jenkins resigned from the Board of Directors, with no explanation by the Company for his departure. Compl. ¶ 27(c).
By around March 15, 2017, Peter Lynch too had departed as the Companys CFO, PAO, and PFO, with no explanation by Company for his departure. Compl. ¶ 27(d). Upon Peter Lynchs departure, Douglas West, formerly MusclePharms
Vice President of Finance and Administration, became the Companys interim PAO and PFO. Compl. ¶ 27(e). By around June 7, 2017, Michael Doran resigned from the Board of Directors, with no explanation by the Company for his departure.
Compl. ¶ 27(f). At this point (on or about June 7, 2017), the entire Board had turned over since Drexlers appointment as its Chairman, with the exception of Defendant Bush, who was appointed to the Board less than a month prior to
Drexlers appointment as Chairman. Compl. ¶ 27(f). By around July 7, 2017, the Boardi.e., Drexler and Bushhad appointed Defendant Casutto as a management director and Defendant Desmond as a
so-called
independent director. By this time, though, Douglas West had departed as the Companys interim PAO and PFO, with no explanation by the Company for his departure. Compl. ¶ 27(g).
Upon Mr. Wests departure, Paul Anton became the Companys interim PAO and PFO, but by on or around September 15, 2017, Mr. Anton had also departed, with no explanation by the Company for his departure. Compl. ¶ 27(h).
|